Johnson & Johnson said on March 4 that it has launched an online channel to sell certain prescription medications directly to U.S. patients who do not have insurance or who purchase medicines with out-of-pocket cash payments. The site, called J&J Direct, currently lists three branded products: the diabetes medicines Invokana and Invokamet, and the anticoagulant Xarelto.
The company framed the site as part of a broader pledge to expand direct access to its medicines. That pledge stems from an agreement the company reached in January with the U.S. administration in which Johnson & Johnson committed to lower drug prices in exchange for exemptions from tariffs.
In a related commitment made last year, the company said it would invest $55 billion in the United States over a four-year period. The recent website launch follows a series of engagements between the U.S. government and the pharmaceutical industry on drug pricing and access.
The Trump administration has negotiated agreements with 16 drug companies intended to lower medicine costs for the government’s Medicaid program and for consumers who pay cash, with an explicit goal of narrowing the gap between U.S. drug prices and those in other wealthy countries.
Other pharmaceutical firms have moved into direct-to-consumer channels as well. Several companies, including Pfizer and Eli Lilly, have already introduced their own online platforms selling prescription medicines directly to patients.
The U.S. government has also launched a website, TrumpRx.gov, which lists discounted prescription medicines as part of the administration’s effort to reduce drug costs. Johnson & Johnson is not currently selling any medicines through TrumpRx.gov, but the company has agreed to participate in that government initiative.
Separately, promotional material associated with the company’s coverage notes a service called ProPicks AI that evaluates JNJ among other companies using more than 100 financial metrics and highlights past performance examples. That promotional copy states the AI has identified notable past winners, listing Super Micro Computer and AppLovin with specific percentage gains, and invites readers to explore whether JNJ appears in any ProPicks AI strategies.
Context and takeaways
- J&J Direct currently lists three medicines by brand name: Invokana, Invokamet and Xarelto.
- The website launch is connected to an agreement made in January with the U.S. administration to reduce prices in exchange for tariff exemptions, and follows a prior commitment to invest $55 billion in the U.S. over four years.
- The move occurs amid a broader government push that has produced agreements with 16 pharmaceutical companies and the creation of a government-discount site, TrumpRx.gov.